Epiminder’s Minder Procedure Wins 13% Medicare Payment Increase
EPI: $0.265 +10.42% · MC: $61M
US Medicare has increased the national hospital outpatient payment for Epiminder’s Minder implant procedure by 13% for calendar 2027. The payment covers hospital procedure costs, including the device, and is adjusted for local wages; it is not revenue paid directly to Epiminder. The decision follows last week’s FDA clearance expanding Minder’s use to adolescents with drug-resistant epilepsy. Epiminder expects enrolment in its DETECT study to reach 125 participants by December, up from 100 in mid-October.

Comments